Navigation Links
Insmed to Present at Stifel Nicolaus 2012 Healthcare Conference
Date:8/30/2012

MONMOUTH JUNCTION, N.J., Aug. 30, 2012 /PRNewswire/ -- Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company dedicated to the development of innovative inhaled pharmaceuticals for the treatment of serious lung infections, today announced that Timothy Whitten, President and Chief Executive Officer, will be presenting a corporate overview at the Stifel Nicolaus 2012 Healthcare Conference in Boston on Thursday, September 6, 2012, at 8:35 AM ET.

A live audio webcast will be made available on Insmed's website, http://www.insmed.com.  The webcast will also be archived for 30 days.

About Insmed
Insmed Incorporated is a biopharmaceutical company dedicated to the development of innovative inhaled pharmaceuticals for the treatment of serious lung infections, with a particular focus on orphan diseases.  Insmed's core expertise is the development of inhaled antibiotic therapy delivered via proprietary advanced liposomal pulmonary technology.  For more information, please visit http://www.insmed.com.

Forward-Looking Statements
This release contains forward-looking statements which are made pursuant to provisions of Section 21E of the Securities Exchange Act of 1934. Investors are cautioned that such statements in this release, including statements relating to our financial position, our estimates regarding our capital requirements and our needs for additional financing, our ability to access additional funds under the Hercules loan agreement, results of operations, the status, results and timing of results of pre-clinical studies and clinical trials and pre-clinical and clinical data described herein, the timing of and costs associated with pre-clinical studies and clinical trials, the development of our products, our estimates of the size of the potential markets for our product candidates, and the business strategies, plans and objectives of management, constitute forward-looking statements which involve risks and uncertainties that could cause actual results to differ materially from those anticipated by the forward-looking statements.  Our results may be affected by such factors as the receipt and timing of U.S. Food and Drug Administration and other regulatory reviews and approvals, if at all, competitive developments affecting our product development, delays in product development or clinical trials, and patent disputes involving currently developing products.  The risks and uncertainties include, without limitation, we may experience unexpected regulatory actions, delays or requests, our future clinical trials may not be successful, we may be unsuccessful in developing our product candidates or receiving necessary regulatory approvals, we may experience delays in our product development or clinical trials, our product candidates may not prove to be commercially successful, our expenses may be higher than anticipated, and other risks and challenges detailed in our filings with the U.S. Securities and Exchange Commission, including our Annual Report on Form 10-K for the year ended December 31, 2011 and our Quarterly Report on Form 10-Q for the quarter ended June 30, 2012.  Investors are cautioned not to place undue reliance on any forward-looking statements which speak only as of the date of this release.  We undertake no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances that occur after the date of this release or to reflect the occurrence of unanticipated events.

Investor Relations Contact:
Brian Ritchie – FTI Consulting
212-850-5683
brian.ritchie@fticonsulting.com

Media Contact:
Irma Gomez-Dib – FTI Consulting
212-850-5761
irma.gomez-dib@fticonsulting.com


'/>"/>
SOURCE Insmed Incorporated
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Insmed Announces Financial Results For Second Quarter And Six-months Ended June 30, 2012
2. Insmed Secures $20 Million Loan Agreement With Hercules Technology Growth Capital
3. Insmed Incorporated Provides Corporate Update
4. Epigenomics, Present and Future Applications for Pharmaceuticals and Diagnostics: Twease.org
5. Life Technologies to Present at UBS Global Life Sciences Conference
6. Companies Selected to Present at AdvaMed 2012 Announced
7. Walgreens Set to Present at CBIs 3rd Forum on Strategic Distribution Planning for Specialty Products
8. MAP Pharmaceuticals to Present at Upcoming Investor Conferences
9. Auxilium Pharmaceuticals, Inc. to Present at the Canaccord Genuity 32nd Annual Growth Conference
10. MiMedx Group to Present at the Canaccord Genuity Annual Growth Conference
11. Robert Kirsner, MD, PhD, To Present Results For Phase 2b 6-Month Follow-Up Trial Of Unique Investigational Cell-Based Therapy For Venous Leg Ulcers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... Oakland, California (PRWEB) , ... March 28, 2017 , ... ... that its flagship product, AllegroGraph , has been named a ‘Champion’ by Bloor ... “AllegroGraph is the highest ranked product in its class, and, thanks to Gruff, it ...
(Date:3/28/2017)... WASHINGTON , March 28, 2017  (AACR17, Booth ... sequencing during the American Association for Cancer Research (AACR) ... in Washington, D.C. , April 1-5, ... expression of thousands of cells at the individual level. ... Experts on-hand at AACR to discuss expanded next ...
(Date:3/28/2017)... HOLLISTON, Mass. , March 28, 2017 ... "Company"), a biotechnology company developing bioengineered organ implants to ... bronchus and trachea, today announced that Jim McGorry, ... 3D Printing and BioEngineering panel at the ... 2017 at 2:30 PM ET in Cambrige, Massachussetts. The ...
(Date:3/28/2017)... 2017 /PRNewswire/ -RepliCel Life Sciences Inc. (OTCQB: REPCF) (TSXV: RP) ... safety and clinical data from its phase 1/2 tendon repair ... follicle-derived fibroblasts (RCT-01) as a treatment for Achilles tendinosis. ... The ... profile at 6 months and showed no serious adverse events ...
Breaking Biology Technology:
(Date:2/28/2017)... , Feb. 28, 2017   Acuant , a ... globally, announces significant enhancements to new and core technologies ... New products include mobile and desktop Acuant FRM TM ... - a real time manual review of identity ... technology provides the fastest and most accurate capture software ...
(Date:2/26/2017)... -- Securus Technologies, a leading provider of civil and ... corrections and monitoring, announces the appointment of a ... often, too many offenders return to jail or ... to tackle this ongoing problem and improve the ... significant steps are underway, Securus continues to invest ...
(Date:2/21/2017)... -- Der weltweite Biobanking-Sektor wird bis zum ... mit mehr als 50 Vertretern aus verschiedenen Branchen wurde aber ... diese Prognose zu realisieren. ... Zu den Schwierigkeiten für ... für die Biobank, die Implementierung Zeit sparender Technologien, ein ...
Breaking Biology News(10 mins):